Share Issue/Capital Change • Jan 31, 2023
Share Issue/Capital Change
Open in ViewerOpens in native device viewer

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes.
During January, the number of shares and votes in BONESUPPORT HOLDING AB (PUBL) has increased with 22,000 due to the exercise of 110,000 warrants within the employee stock options program 2012/2022.
As per January 31, 2023, the total number of shares in BONESUPPORT HOLDING AB (publ) amounts to 66,196,635 shares, divided into 64,554,197 ordinary shares with one vote per share and 1,642,438 series C-shares with one-tenth of a vote per share, corresponding to a total of 64,718,440.8 votes.
BONESUPPORT Holding AB Emil Billbäck, CEO +46 (0) 46 286 53 70
Håkan Johansson, CFO +46 (0) 46 286 53 70 [email protected]
Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 [email protected] www.cordcom.se
This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-01-31 09:00 CET.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport. com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
Press Release 31 January 2023 09:00:00 CET

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.